Artrya Limited (ASX:AYA)
Australia · Delayed Price · Currency is AUD | Market Cap | 539.41M +49.2% |
| Revenue (ttm) | 28.00K |
| Net Income | -25.18M |
| EPS | -0.17 |
| Shares Out | 162.96M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,910,417 |
| Open | 3.200 |
| Previous Close | 3.150 |
| Day's Range | 3.100 - 3.310 |
| 52-Week Range | 2.370 - 6.490 |
| Beta | 0.65 |
| Analysts | Strong Buy |
| Price Target | 5.99 (+80.97%) |
| Est. Earnings | Nov 24, 2026 |
About Artrya
Artrya Limited, a medical technology company, engages in the development and commercialization of artificial intelligence platform that detects, diagnoses, and address coronary artery disease in Australia. It offers Salix, a suite of cloud-based software that uses artificial intelligence to automate the detection of coronary artery disease from coronary computed tomography angiography scans to identify and manage patients at risk of a heart attack. The company was incorporated in 2018 and is based in West Perth, Australia. [Read more]
Financial Performance
In fiscal year 2026, Artrya's revenue was 28,000, a change of 0.00% compared to the previous year's 28,000. Losses were -25.18 million, 53.5% more than in 2025.
Financial StatementsAnalyst Summary
According to 3 analysts, the average rating for AYA stock is "Strong Buy." The 12-month stock price target is $5.99, which is an increase of 80.97% from the latest price.
News
Artrya Transcript: Status update
A five-year Huntsville agreement converts the first SAPPHIRE participant into a commercial customer and establishes the largest U.S. deployment to date. The AUD 500,000 minimum covers anatomy, with additional plaque and flow revenue potential as utilization expands and flow clears.
Artrya Annual report: H2 2026
Artrya has published its H2 2026 annual report on August 18, 2026.
Artrya Quarterly report: H1 2026
Artrya has published its H1 2026 quarterly earnings report on February 24, 2026.
Artrya Earnings Call Transcript: Q2 2026
Converted all U.S. foundation partners to commercial contracts, launched first Plaque module revenues, and secured six major SAPPHIRE study sites. Strong cash position of AUD 76.5 million supports FDA submission and U.S. expansion, with full customer ramp-up targeted for FY 2027.
Artrya Earnings release: Q2 2026
Artrya released its Q2 2026 earnings on February 1, 2026, summarizing the period's financial results.
Artrya Transcript: Bell Potter Healthcare Conference 2025
A real-time, AI-driven coronary CT platform is set to transform cardiac care by streamlining hospital workflows, improving patient outcomes, and delivering strong financial returns. With foundation customers committed and a robust U.S. go-to-market plan, break-even is targeted by FY2027.
Artrya Transcript: AGM 2025
The AGM highlighted a successful transition to commercial operations, strong U.S. market entry, and robust financial planning. Key FDA clearances, strategic partnerships, and a focus on high-margin SaaS growth were discussed, with profitability targeted for FY 2027-2028.
Artrya Slides: FY 2025
Artrya has posted slides in relation to its FY 2025 quarterly earnings report, which was published on November 12, 2025.
Artrya Earnings Call Transcript: Q1 2026
Technical integration and commercial negotiations with U.S. partners are progressing, with FDA clearance for the Salix Coronary Plaque module and a strong $80 million capital raise supporting U.S. expansion. Cash outflows rose due to scaling, but the company remains well-funded and targets break-even by FY2027.
Artrya Earnings release: Q1 2026
Artrya released its Q1 2026 earnings on October 28, 2025, summarizing the period's financial results.
Artrya Annual report: H2 2025
Artrya has published its H2 2025 annual report on October 12, 2025.